Navigation Links
RegenoCELL Gives Second Half Update
Date:7/12/2011

NATICK, Mass., July 12, 2011 /PRNewswire/ -- RegenoCELL Therapeutics, Inc. (OTCBB: RCLL) – gave a second half update.  James F. Mongiardo, Chief Executive Officer, reported that plans are being made for the conduct of clinical trials in the United States and Europe for its stem cell therapy. Simultaneous with these efforts, the company's foreign subsidiary, Regenocell, Ltd., reported that it expects to begin marketing the company's stem cell product for the treatment of congestive heart failure and peripheral artery disease.  Sales have been previously made through distributors.

In the second half, Regenocell, Ltd. expects to increase revenues through direct sales, additional distributors and offering the autologous stem cell treatment in more countries.

About RegenoCELL Therapeutics, Inc.

RegenoCELL Therapeutics, Inc. is a stem cell therapy company using adult stem cells for autologous treatment of patients.  The Company plans to obtain regulatory approval in the United States and the European Community to market its stem cell treatments.  Through its wholly owned foreign subsidiaries, the company is marketing its stem cell treatments for transplantation in jurisdictions where autologous therapy is permitted.

Cardiac Disease

There are therapies to treat congestive heart failure.  But there comes a treatment point when the only option may be a heart transplant.  Over 25,000 people are on the transplant lists but fewer than 2,500 receive one. The mean life expectancy of a heart transplant recipient is 8 years. A new therapeutic approach to treat this disease is needed.

Peripheral Artery Disease

The same RCLL adult stem cell treatment can be used to treat peripheral artery disease. In the United States, there are over 10 million people suffering from the lack of sufficient blood flow to the extremities with an equal number in Europe. This disease is most often experienced by diabetics in their toes and lower legs.

Since 2005, the company's stem cell therapy has successfully treated over 500 patients.  The typical patient is suffering from congestive heart failure with no treatment options and 3 to 6 months to live.  Less than a half liter of blood is extracted from the patient and sent to the company's subsidiary cell processing facility in Israel.  There the patient's stem cells are extracted and grown from tens of thousands into many millions.  The stem cells are primed for angiogenesis or blood vessel formation.  The patient then travels to a jurisdiction where autologous therapy is permitted and has the stem cells transplanted in a hospital in a catheterization laboratory in a procedure similar to angioplasty.

Forward-Looking Statements:

Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward- looking statements.  These risk factors include, without limitation (i) our ability to obtain additional financing; (ii) our ability to control our expenses; (iii) our ability through our wholly owned foreign subsidiaries to manufacture and market our stem cell treatments; (iv) our ability to initiate and timely complete clinical trials; (v) the timing of and our ability to obtain and maintain regulatory approvals for our stem cell treatments; (vi) our dependence on the success of our lead stem cell treatment; (vii) our inability to predict the extent of our future losses or if or when we will become profitable; (viii) our ability to protect our intellectual property rights; and, (ix) intense competition.  The Company is also subject to the risks and uncertainties described in our filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2010 and its Quarterly Report on 'From 10-Q for the quarter ended March 31, 2011.

Contact:

RegenoCELL Therapeutics, Inc.
James F. Mongiardo, Chief Executive Officer
+1-508-647-4065, jmongiardo@regenocell.com


'/>"/>
SOURCE RegenoCELL Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Treatment Gives Lung Cancer Patients With Inoperable Tumors Two Years or More
2. Large Study Gives Nod to Drug-Eluting Stents in Heart Attack
3. St. Jude Study Gives New Insights Into How Cells Accessorize Their Proteins
4. New Research Gives Insight to the Frequency of Doctor Shopping Occurring Within Prescription Monitoring Programs
5. NASDAQ Gives Dynatronics a Second Six-Month Extension for Minimum Bid Price Compliance
6. Frost & Sullivan Market Study Gives Thumbs Up for Pepex™ Trio™ One-Click™ Blood Glucose Meter
7. Serious Eye Disease Gives Birth to Invention of Major New Eye Care Device
8. CareFusion Launches Innovative Vertebral Balloon That Gives Surgeons More Options to Treat Spinal Fractures
9. Web Pharmacy Rxbuys.com Gives Its Customers a 5% Discount Coupon
10. Bureau of Prescription Health Gives the Whole Truth (and Nothing But) About Free Medicine at FreeMedicine.com
11. Spherix Reports Second Quarter Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... Inc. (NYSE: HRC), will host its fiscal third quarter 2017 ... beginning at 7:30 a.m. (CDT) / 8:30 a.m. (EDT). ... the conference call, dial (877) 304-8969 (domestic) or (631) 291-4543 ... prior to the start to allow time to connect. The ... Webcast: A simultaneous webcast of the call will be ...
(Date:6/16/2017)... 16, 2017 Datascope Corp. is voluntarily performing a worldwide field ... potential electrical test failure code.     ... PART NUMBER ... IABP 0998-UC-0446HXX; 0998-UC-0479HXX ... This field correction also ...
(Date:6/14/2017)... Va. , June 14, 2017  ivWatch LLC, ... and effectiveness of intravenous (IV) therapy, is pleased to ... the category of Nonsurgical Hospital Supplies and Equipment at ... awards program for the medtech industry. The award was ... the Jacob K. Javits Center in New ...
Breaking Medicine Technology:
(Date:6/25/2017)... ... June 25, 2017 , ... June is Men’s Health Month and the focus ... cancer among men in the U.S. and the third most common cause of cancer related ... one man in seven will be diagnosed with prostate cancer during his lifetime. Those ...
(Date:6/24/2017)... ... June 24, 2017 , ... The Pennsylvania Athletic Trainers’ Society’s ... and Erie Convention Center on June 8-10. The weekend consisted of many ... award and scholarship presentations, and professional networking. , On Friday June 9th, ...
(Date:6/24/2017)... (PRWEB) , ... June 24, 2017 , ... The weather ... spend time outdoors. Home and business owners should be aware that the summer months ... lake. In fact, mechanical locks and keys can be negatively affected from direct exposure ...
(Date:6/23/2017)... Providence, RI (PRWEB) , ... June 23, 2017 ... ... Community Care Network today announced the launch of Care Management Alerts and Dashboards, ... for 140,000 patients throughout Rhode Island. , RIQI’s Care Management Alerts and Dashboards ...
(Date:6/23/2017)... ... June 23, 2017 , ... By scoring 100% for fiscal management and accountability, ... premier online charity evaluator, Charity Navigator, validating ANRF's work as a top charity in ... by Charity Navigator and earns ANRF a spot on their “ 10 Charities Worth ...
Breaking Medicine News(10 mins):